沙利度胺联合EP方案对小细胞肺癌患者无进展生存期的影响

Influence of Progression-Free Survival of Therapy with Cisplatin Plus Etposide with Thalidomide in Patients with Small Cell Lung Cancer

目的观察沙利度胺联合EP(依托泊苷、顺铂)方案治疗小细胞肺癌(small cell lung cancer,SCLC)对患者无进展生存期(PFS)的影响。方法将SCLC 50例随机分为联合治疗组25例(采用沙利度胺联合EP方案治疗)、单纯化疗组25例(仅采用EP方案治疗),总计治疗6周期。6周期治疗完成后评价两组PFS状况及药物安全性。结果 6周期治疗完成后联合治疗组14例、单纯化疗组11例可评价。联合治疗组和单纯化疗组PFS分别为4.81个月和4.27个月,两组比较差异无统计学意义(F=0.01,P=0.32)。治疗及观察期间,两组血常规、肝肾功能及心电图检查均未发现明显变化,皆未出现不良事件或与治疗药物相关的不良反应。结论沙利度胺联合EP方案治疗SCLC对患者PFS无明显影响。

Objective To observe the influence of the progression-free survival （PFS） in the small-cell lung cancer （SCLC） patients treated by Cisplatin plus Etposide with Thalidomide. Methods A total of 50 SCLC patients were included and randomly divided into therapeutic alliance group （25 cases） and only chemotherapy group （25 cases）. Patients in the therapeutic alliance group were treated with Cisplatin plus Etposide and Thalidomide, and patients in the chemotherapy simple group were treated with Cisplatin plus Etposide for a total of 6 cycles, after which PFS of two groups and drug safety were evaluated. Results The 14 patients in the therapeutic alliance group, and the other 11 patients in the chemotherapy simple group were evaluated after the 6- cycle chemotherapy. The PFS was 4.81 months in the therapeutic alliance group vs. 4.27 months in the chemotherapy group, and there was no significant difference between the two groups （F = 0. 01, P = 0.32）. There were no significant changes between the blood routine, liver and renal function and electrocardiogram of the two groups during treatment and observation. Conclusion Treatment by Cisplatin plus Etposide with Thalidomide can not prolong PFS in patients with SCLC.